Clinical Trials for Cervical Cancer

A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced or metastatic solid tumors that have progressed after their most recent therapy receive investigational BMS-986340 alone or with nivolumab or docetaxel. BMS-986340 is an anti-CCR8 antibody designed to deplete tumor regulatory T cells.

ClinicalTrials.gov ID: NCT04895709

An Open-Label, Multicenter, Phase 1/1b Study of JANX008 in Subjects with Advanced or Metastatic Solid Tumor Malignancies

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable, locally advanced or metastatic EGFR-expressing solid tumors who have progressed on or cannot tolerate established therapies receive weekly intravenous JANX008, a protease-activated, masked EGFR×CD3 T-cell engager designed to activate in the tumor microenvironment. The sponsor has discontinued JANX008 development because of insufficient magnitude and consistency of activity.

ClinicalTrials.gov ID: NCT05783622

A Phase 1, Open Label, Dose-Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics and Initial Therapeutic Activity of AVA6000, a Novel FAP-activated Doxorubicin Prodrug Administered Intravenously in Patients With Locally Advanced or Metastatic Selected Solid Tumours

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with good performance status and selected locally advanced unresectable or metastatic solid tumors—including certain sarcomas, salivary gland cancer, and triple-negative breast cancer—receive intravenous AVA6000 alone. This investigational prodrug is designed to release doxorubicin when cleaved by fibroblast activation protein (FAP) in tumor-associated stroma.

ClinicalTrials.gov ID: NCT04969835

A Phase 1 Study of SGN-PDL1V in Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with metastatic or unresectable solid tumors and ECOG 0–1 receive PF-08046054, a PD-L1-targeted antibody–drug conjugate that delivers the microtubule inhibitor MMAE, alone or with the PD-1 inhibitor pembrolizumab. Combination cohorts are limited to PD-L1-positive NSCLC or head and neck squamous cell carcinoma.

ClinicalTrials.gov ID: NCT05208762

A PHASE 1A/B OPEN-LABEL MASTER STUDY OF PF-07799544 AS A SINGLE-AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This study enrolls patients with previously treated advanced solid tumors, including primary brain tumors, for PF-07799544, an investigational brain-penetrant MEK inhibitor. Combination cohorts enroll patients with BRAF-altered advanced melanoma or nonmelanoma solid tumors to receive PF-07799544 with PF-07799933, an investigational brain-penetrant BRAF inhibitor; an initial component may use encorafenib instead.

ClinicalTrials.gov ID: NCT05538130

A Global First-in-Human Study in NSCLC, HNSCC and Solid Tumors With ABBV-514 as a Single Agent and in Combination With Budigalimab

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with ECOG 0–1 and refractory advanced solid tumors are eligible for dose escalation; expansion focuses on unresectable or metastatic NSCLC or HNSCC previously treated with platinum chemotherapy and PD-1/PD-L1 blockade, excluding NSCLC with known EGFR mutations or ALK rearrangements. Patients receive intravenous ABBV-514, an investigational anti-CCR8 antibody designed to deplete tumor-infiltrating regulatory T cells, alone or with budigalimab, an investigational anti-PD-1 antibody.

ClinicalTrials.gov ID: NCT05005403

A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1310 in Subjects With Advanced/Metastatic Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced, unresectable or metastatic solid tumors, generally after standard therapy, receive DB-1310, a HER3-targeted antibody–drug conjugate delivering a topoisomerase I inhibitor, alone or with trastuzumab or osimertinib in selected cohorts. Expansion cohorts include molecularly defined lung, breast, prostate, head and neck, esophageal, and biliary tract cancers; selected osimertinib combination cohorts enroll previously untreated EGFR-mutated NSCLC.

ClinicalTrials.gov ID: NCT05785741

An Open-label, Phase 1, Multicenter Study to Evaluate the Safety and Preliminary Anti-tumor Activity of NT-175 in Human Leukocyte Antigen-A*02:01-Positive Adult Subjects With Unresectable, Advanced and/or Metastatic Solid Tumors That Are Positive for the TP53 R175H Mutation

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with HLA-A*02:01-positive, TP53 R175H-mutant unresectable advanced or metastatic solid tumors who have received at least one approved systemic regimen and have no curative option receive lymphodepleting chemotherapy followed by a single NT-175 infusion and interleukin-2. NT-175 is an autologous T-cell therapy engineered with a T-cell receptor targeting HLA-A*02:01-presented TP53 R175H and edited to reduce TGF-β-mediated suppression.

ClinicalTrials.gov ID: NCT05877599

A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: This trial enrolls adults with previously treated, locally advanced or metastatic, HER2 IHC 3+ solid tumors (excluding biliary tract cancers) who have progressed after at least one prior systemic therapy and lack standard treatment options; patients receive zanidatamab, a bispecific antibody targeting two HER2 epitopes. Eligible patients must have measurable disease, ECOG 0–1, and no active CNS metastases.

ClinicalTrials.gov ID: NCT06695845

An Open-Label Phase 1/2A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Advanced and/or Refractory Solid Tumor Malignancies

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated, progressive advanced solid tumors and no suitable standard therapy receive GV20-0251 alone or with pembrolizumab; expansion cohorts focus on selected tumor types, including melanoma, NSCLC, head and neck and endometrial cancers, and pMMR/MSS colorectal cancer in combination cohorts. GV20-0251 is an investigational antibody targeting IGSF8, a proposed innate immune checkpoint.

ClinicalTrials.gov ID: NCT05669430